Background
- Folate receptor alpha (FR⍺) is the target of several antibody drug conjugates including mirvetuximab soravtansine-gynx (MIRV).
- FR⍺ expression may be dynamic, with some FR⍺-high tumors converting to FR⍺-low (Manning 2024, Martin 2024).
- FR⍺ expression and MIRV outcomes are established in high-grade serous ovarian carcinoma (HGSOC), but little is known about non-HGSOC histologies.
- Compared to immunohistochemistry (IHC), RNAsequencing (seq) may better represent FR⍺ status, and in turn, MIRV time on treatment (ToT)